Floatz logo

Cyclophosphamide

Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

BGI, ChinaSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Alice Mims
Phase 3BBB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 3BBB
Idarubicine
The First Affiliated Hospital of Soochow University
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →